Autoimmune hemolytic anemia (ALHA) cardioplegic solution and preparation method thereof

A cardioplegia solution and solution technology, applied in the field of cardioplegia, can solve problems such as prone to arrhythmia, prone to inflammatory reactions, and long arrest time, so as to improve the success rate of a relapse and shorten the arrest Time, the effect of avoiding the damage of the myocardium

Inactive Publication Date: 2013-06-12
THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The present invention provides a kind of ALHA cardioplegia solution and its preparation method, overcomes the deficiency of above-mentioned prior art, it can effectively solve traditional cardioplegia solut

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Autoimmune hemolytic anemia (ALHA) cardioplegic solution and preparation method thereof
  • Autoimmune hemolytic anemia (ALHA) cardioplegic solution and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1, the ALHA cardioplegia solution contains 552.86mg to 947.76mg of adenosylcobalamin, 4.739ml to 5ml of lidocaine solution with a mass concentration of 2%, and pentazocine per 500ml of the ALHA cardioplegia solution. 30mg to 60mg, 4.1ml to 10ml of magnesium sulfate solution with mass concentration of 25%, 3.725ml to 5ml of potassium chloride solution with mass concentration of 10%, 4.3ml to 10ml of calcium gluconate solution with mass concentration of 10%, and the balance Acetate Ringer's solution; wherein, the ALHA cardioplegia solution is obtained by the following method: at a room temperature of 22°C to 26°C, oxygen is injected into the hyperoxic liquid at an oxygen flow rate of 2 L / min to 4L / min. In the instrument, the oxygen after the reaction is fed into the required amount of Ringer's acetate for dissolved oxygen activation treatment, and after dissolving oxygen, it is prepared into a hypertonic oxygen ringer's acetate whose partial pressure of oxygen in t...

Embodiment 2

[0022] Example 2, the ALHA cardioplegia solution contains 552.86 mg or 947.76 mg of adenosylcobalamin, 4.739 ml or 5 ml of lidocaine solution with a mass concentration of 2%, and pentazocine in every 500 ml of the ALHA cardioplegia solution. 30mg or 60mg, 4.1ml or 10ml of magnesium sulfate solution with mass concentration of 25%, 3.725ml or 5ml of potassium chloride solution with mass concentration of 10%, 4.3ml or 10ml of calcium gluconate solution with mass concentration of 10%, and the balance Acetate Ringer's solution; wherein, the ALHA cardioplegia solution is obtained by the following method: at a room temperature of 22 ° C or 26 ° C, oxygen is injected into the hyperoxic liquid at an oxygen flow rate of 2 L / min or 4 L / min. In the instrument, the oxygen after the reaction is fed into the required amount of Ringer's acetate for dissolved oxygen activation treatment, and after dissolving oxygen, it is prepared into hypertonic oxygen Ringer's acetate with an oxygen partial p...

Embodiment 3

[0023] Embodiment 3, the preparation method of this ALHA cardioplegia solution, every 500ml of this ALHA cardioplegia solution contains adenosylcobalamin 552.86mg to 947.76mg, mass concentration is 2% lidocaine solution 4.739ml to 5ml, spray Tazocine 30mg to 60mg, 25% magnesium sulfate solution 4.1ml to 10ml, 10% potassium chloride solution 3.725ml to 5ml, 10% calcium gluconate solution 4.3ml to 10ml and the remaining amount of Ringer's acetate solution; wherein, the preparation method of the ALHA cardioplegia solution is carried out according to the following steps: at a room temperature of 22°C to 26°C, with an oxygen flow rate of 2 L / min to 4L / min Input oxygen into the hyperoxic liquid preparation apparatus, and pass the reacted oxygen into the required amount of acetic acid Ringer's solution for oxygen-dissolving activation treatment. After dissolving oxygen, prepare a hypertonic liquid with an oxygen partial pressure of 100kPa to 120kPa in the solution. Oxygenated Ringer'...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of a cardioplegic solution, and in particular relates to an autoimmune hemolytic anemia (ALHA) cardioplegic solution and a preparation method thereof. Every 500ml of the ALHA cardioplegic solution contains 552.86-947.76mg of cobamamide, 4.739-5ml of a lidocaine solution of 2% in mass concentration, 30-60mg of pentazocine and 4.1-10ml of a magnesium sulfate solution of 25% in mass concentration. The cardioplegic solution disclosed by the invention can effectively shorten duration of induced cardiac arrest; and the ALHA cardioplegic solution can carry oxygen, so that just few ALHA cardioplegic solution can effectively promote cardiac arrest to avoid hurt of myocardial ischemia reperfusion to cardiac muscle, further improve re-beating success rate in one time and reduce arrhythmia incidence rate after re-beating, and effectively relieve an inflammatory response, so as to effectively protect the cardiac muscle cell.

Description

technical field [0001] The invention relates to the technical field of cardioplegia solution, and relates to an ALHA cardioplegia solution and a preparation method thereof. Background technique [0002] Since the beginning of heart surgery in the 1960s, pioneers in cardiac surgery have attempted several ways to support the patient's circulation on the one hand and protect the heart on the other. The protective effect of hypothermia has been recognized not only locally in the heart but also in systemic applications. The subsequent development of cardiac surgery has mainly utilized the gradual improvement of extracorporeal circulation components, allowing more and more complex and longer operations to be performed, but unfortunately, the myocardial protection effect has not reached the ideal state, and cardiac arrest still exists after surgery - Reperfusion injury. Therefore, it is necessary to provide a measure of myocardial protection that is better than merely cooling the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/14A61P9/00A61K33/06A61K33/00A61K31/714A61K31/439A61K31/167
Inventor 郑宏王江陈春玲马明闵晓艳
Owner THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap